1. Pink Sheet
  2. >>Compliance

FDA's Rollout of New Inspection Protocols May Begin Next Year

 
• By Bowman Cox

Despite great enthusiasm within the agency for a New Inspection Protocols Pilot Project, FDA officials are saying they don't expect to adopt the protocols for broader use in pharmaceutical facility preapproval and surveillance inspections until perhaps sometime in 2017. The protocols could make inspections more comparable – and could bring recognition to facilities that go beyond compliance.

FDA's New Inspection Protocols Project is proceeding at a slower pace than agency officials were hoping a year ago, which means FDA won't begin using the protocols on a routine basis until next year at the earliest.

The promise of NIPP: inspections that are more comparable from one site to another and from one investigator to another...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Compliance

Under Trump, Antitrust Regulators May Be More Divestiture Friendly

 
• By Tim Casey

The Trump Administration may differ from the Biden Administration in some areas of health care antitrust enforcement, but experts said some Biden-era priorities may be maintained.

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US Tariffs And Geopolitical Tensions Push EU To New Trade Routes And Infrastructure Growth

 
• By Francesca Bruce

The EU is diversifying its trading partners, which means that new markets may open up to the pharmaceutical industry, countering transatlantic tensions.

More from Pink Sheet

CDC Should Boost Vaccine Monitoring Transparency, Communication - National Academies Report

 
• By Sue Sutter

The Immunization Safety Office leveraged a “coordinated network of complementary surveillance systems” to monitor COVID-19 vaccine risks during the pandemic, but its communications faced challenges and were often intertwined with CDC efforts to promote vaccination, NASEM report finds.

Galderma’s Post Hoc Analysis Supports Nemluvio Claims But Clearer Disclosures Needed, NAD Says

 
• By Cathy Kelly

Claims for the dermatological appearing on websites and social media were challenged by Dupixent marketer Sanofi. Galderma said it would comply with the National Advertising Division’s recommendations, a move that underscores the challenging times for DTC advertisers.

Former CBER Director Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.